News & Analysis as of

Genentech Celltrion

Venable LLP

The First Biosimilar Disputes at the Unified Patent Court (UPC)

Venable LLP on

As the era of biologics and biosimilar litigations heats up in the United States, Europe’s Unified Patent Court (UPC) is also taking center stage with the first two biosimilar disputes filed in March and April....more

Goodwin

Genentech and Partners Voluntarily Dismiss IPR Appeals Related to Genentech’s ACTEMRA® (Tocilizumab)

Goodwin on

​​​​​​​On February 12, 2024, Chugai, Genentech, and Hoffmann-La Roche filed a motion for voluntary dismissal of their appeals of the PTAB’s Final Written Decisions in IPR2022-00578 and IPR2022-00579. The appeals concerned...more

Goodwin

PTAB Grants Petitioner Celltrion’s Motion To Submit Supplemental Information in Tocilizumab IPR

Goodwin on

​​​​​​​The U.S. Patent Trials & Appeals Board (Board) recently issued an Order granting Celltrion’s motion to submit supplemental information in its IPR (2022-00578) against U.S. Pat. No. 8,580,264, owned by Chugai Seiyaku...more

Goodwin

Year in Review: The Top-Five U.S. Biosimilar Market Developments of 2019

Goodwin on

As we start the new year, we look back at the top U.S. biosimilar market developments of 2019. Here are some of our highlights, in no particular order...more

Goodwin

Teva and Celltrion Launch Rituximab Biosimilar in US

Goodwin on

On November 7, Teva Pharmaceuticals USA, Inc., and Celltrion, Inc., announced that TRUXIMA® (rituximab-abbs) will be available in the United States beginning November 11. As we previously reported, TRUXIMA® is the first...more

Goodwin

Genentech Settles Rituximab Patent Dispute with Celltrion and Teva

Goodwin on

On November 1, 2018, Genentech and its co-plaintiffs dismissed the lawsuits they brought against Celltrion and Teva under the BPCIA in the District of New Jersey, in which the plaintiffs alleged that Celltrion’s filing of an...more

Goodwin

Biosimilar-Related Appeals Pending before the Federal Circuit

Goodwin on

There are presently seven biosimilar-related appeals pending before the Federal Circuit. Two of those appeals, Amgen v. Sandoz (Case No. 18-1551) and Amgen v. Coherus (Case No. 18-1993), are from district court judgments in...more

Goodwin

Trastuzumab, Rituximab, and Bevacizumab Litigation Updates

Goodwin on

Below is a rundown of some recent developments in BPCIA litigations concerning biosimilars of Genentech’s Herceptin® (trasuzumab), Rituxan® (rituximab), and Avastin® (bevacizumab). Celltrion v. Genentech (trastuzumab) and...more

Goodwin

New BPCIA Litigations Regarding Celltrion’s Trastuzumab and Rituximab Biosimilars

Goodwin on

On January 11, 2018, Celltrion and Teva filed two lawsuits against Genentech in the District Court for the Northern District of California. Case No. 3:18-cv-00274 relates to Celltrion’s Herzuma®, its trastuzumab biosimilar. ...more

Goodwin

Year in Review: Top 5 Biosimilars Deals of 2017

Goodwin on

Here are our picks for the top-5 biggest deals in the world of biosimilars in 2017...more

Goodwin

IPR Updates

Goodwin on

The PTAB remains a busy venue for biologics patents. Here are some IPR updates from the weeks since our last IPR update...more

Goodwin

Recent IPR Updates

Goodwin on

The PTAB has been a busy place for biologics patents in the past few weeks. Here are some of the highlights...more

Goodwin

Pfizer files two IPR petitions on Genentech’s Patent Directed to Methods of Making Humanized Antibodies

Goodwin on

Pfizer, Inc. has filed two petitions (IPR2017-01488 and IPR2017-01489) challenging claims of U.S. Patent No. 6,407,213 (“the’213 patent”). According to the petitions, the ’213 patent is directed to methods of making humanized...more

Goodwin

Celltrion Files Two Petitions for IPR on Genentech’s Herceptin Patent

Goodwin on

Earlier this week, Celltrion filed two petitions for inter partes review of Genentech’s U.S. Patent No. 6,407,213. According to Celltrion’s petitions, the patent is directed to humanized antibodies. ...more

Goodwin

Celltrion Files Two Additional Petitions for IPR of Genentech’s Trastuzumab Patents

Goodwin on

Celltrion has filed two additional petitions for inter partes review of Genentech patents related to trastuzumab: IPR2017-01139, challenging U.S. Patent 6,627,196, and IPR2017-01140, challenging U.S. Patent 7,371,379....more

Goodwin

Celltrion Files Two Additional Petitions for IPR on Genentech’s Trastuzumab Patents

Goodwin on

Celltrion has filed petitions for inter partes review of two patents related to Genentech’s trastuzumab: IPR2017-01121, challenging U.S. Patent 7,846,441, and IPR2017-01122, challenging U.S. Patent 7,892,549. According to...more

Goodwin

Celltrion Files Petition for IPR of Genentech’s Trastuzumab Patent

Goodwin on

Celltrion has filed a petition for inter partes review (IPR2017-00959) of Genentech’s U.S. Patent 8,591,897. According to the petition, the patent is directed to methods of treating a sub-type of breast cancer with a regimen...more

Goodwin

BPCIA Litigation Roundup (Midwinter 2017)

Goodwin on

Below is our midwinter update on the U.S. patent litigations concerning proposed or approved biosimilar products. For additional details, please consult our BPCIA Litigation Summary Chart or our previous quarterly updates...more

18 Results
 / 
View per page
Page: of 1

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
- hide
- hide